1. Home
  2. SKYE vs IVA Comparison

SKYE vs IVA Comparison

Compare SKYE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$3.70

Market Cap

737.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
IVA
Founded
2012
2011
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
737.1M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
SKYE
IVA
Price
$1.18
$3.70
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
★ $68.00
$14.42
AVG Volume (30 Days)
98.4K
★ 2.7M
Earning Date
11-24-2026
09-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$2.82
52 Week High
$11.68
$7.29

Technical Indicators

Market Signals
Indicator
SKYE
IVA
Relative Strength Index (RSI) 44.62 50.24
Support Level $0.26 $3.55
Resistance Level $1.66 $3.76
Average True Range (ATR) 0.20 0.26
MACD -0.00 0.02
Stochastic Oscillator 62.05 22.81

Price Performance

Historical Comparison
SKYE
IVA

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

Share on Social Networks: